PD L1 News and Research

RSS

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023

New approach to stem cell transplantation may overcome immune rejection

Cell and organ transplants can be lifesaving, but patients often encounter long waiting lists due to the shortage of suitable donors.

22 Nov 2023

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

Using oncolytic viruses (OVs) in combination with nanomaterials as a novel approach to cancer treatment.

22 Nov 2023

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

21 Nov 2023

Novel urine-based prognostic model promises to transform bladder cancer treatment

In a study published in the journal Genes & Diseases, researchers from Fudan University, have developed a novel urine-based prognostic model that promises to transform the management and treatment of bladder cancer.

21 Nov 2023

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

24 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy.

19 Oct 2023

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Antiverse Ltd (Antiverse) and GlobalBio, Inc. (GlobalBio) today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.

From Antiverse 16 Oct 2023

Researchers discover a vulnerability in immunotherapy-resistant triple-negative breast cancer

Researchers at Vanderbilt-Ingram Cancer Center have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

5 Oct 2023

Breakthrough study shows immunotherapy can help prevent bladder cancer recurrence

The Alliance for Clinical Trials in Oncology today announced that the Alliance Data and Safety Monitoring Board (DSMB) determined that the phase III AMBASSADOR (A031501) trial met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma.

5 Oct 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.

11 Sep 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

From AMGEN 1 Sep 2023

Light-driven bacteria could be used to target and kill cancer cells

Targeting malignant tumors with high precision is challenging for biomedical researchers. However, this scenario is likely to witness a paradigm shift in the near future, through the use of specially engineered bacteria, that can eliminate malignant cells efficiently.

29 Aug 2023

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Researchers describe molecular signalling regulated by mTOR among memory and exhausted cytotoxic CD8+ T lymphocytes.

18 Aug 2023

Immunotherapy combination extends progression-free survival in patients with melanoma

A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.

17 Aug 2023

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Study identifies gene fusions to understand their relationship with observed pathologies in cancer patients.

8 Aug 2023